[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fQ4fH2XNuFF9dsTcg8HA54fOxdAjO3xpG0xLML67XJJM":8,"$fox_r2gAYtm9VmDvaC3hgkPhOYLI_fT7OI1MTNfHiA0o":55,"$ffcuCsguxshFwYkdcFwQ1D9Yvm0li-Gmj6uxkFu1Jeh8":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},53426,867157,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","刘秋雨","邢台市南和区人民医院","甲状腺乳腺外科","住院医师",13,0,"乳腺癌IV期 靶向治疗用药实用全解","","https://ystcdn.venuertc.com/venue/AI/c586fbfe-a2b9-4d7e-a890-7b2d676c30f8.jpg","\u003Cdiv class=\"material-bg\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌IV期 靶向治疗用药实用全解\u003C/h1>\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(to right, #f8fafc, #eef3fa);\">\n    \u003Cp class=\"material-lead\">\n      说起来，靶向治疗药物和骨保护药物在乳腺癌治疗中越来越普遍。比如吡咯替尼片，正是这类新型靶向药物，唑来膦酸则用于骨代谢调节。这篇指南围绕这两类代表性药品，总结了7个关键用药细节，包括成分、用法用量、常见风险和储存方法。了解这些细节，可以让用药更安全高效。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 剂型与成分：怎么选怎么看 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f3faf7 80%, #e7e1fa 100%); margin-top:24px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">💊\u003C/span> 剂型与成分：怎么选怎么看\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cstrong>吡咯替尼片：\u003C/strong>口服剂型，每片含有特定剂量的吡咯替尼（常见规格 160mg、240mg等），用于HER2靶向治疗。\u003C/li>\n      \u003Cli>\u003Cstrong>唑来膦酸注射液：\u003C/strong>静脉用药，常见浓度 4mg/5ml。属于双膦酸盐类药物，对骨代谢起作用。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：服药前应仔细核对药物包装的有效成分和规格，确保药师发放和实际需求一致。对于口服片剂，要看清剂量，切忌自行掰分。静脉制剂应由医护人员在医疗点严格操作。\n    \u003C/p>\n    \u003Cp class=\"material-case\">\n      临床上有患者误将不同规格吡咯替尼混用，导致效果受影响。用药前，务必对比包装信息。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 02 作用机制简介：为什么要选择这类药 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f6fafe 80%, #fcf3ec 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">📈\u003C/span> 作用机制简介：为什么要选择这类药\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cstrong>吡咯替尼：\u003C/strong>作为HER2靶向药，阻断HER2受体信号通路，抑制肿瘤细胞增殖。\u003C/li>\n      \u003Cli>\u003Cstrong>唑来膦酸：\u003C/strong>抑制骨组织中破骨细胞活性，降低骨吸收速率，从而减少骨相关事件。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      两类药物通过不同机制作用于肿瘤及骨系统，但都讲究精确干预，尽量减少对健康细胞的影响（参考：Xu et al., \"Pyrotinib as an irreversible pan-ErbB receptor tyrosine kinase inhibitor,\" Cancer Commun, 2021）。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 03 服用（给药）时间与使用方法 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #eef8f3 80%, #eec9e0 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">📅\u003C/span> 服用/给药时间与使用方法\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cstrong>吡咯替尼片：\u003C/strong>每日1次，建议在空腹状态下服用。可用温水整片吞服，不建议碾碎后服用。\u003C/li>\n      \u003Cli>\u003Cstrong>唑来膦酸注射液：\u003C/strong>推荐静脉滴注，通常每3-4周一次。滴注过程需30-60分钟。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：口服药每次按医嘱用量，如果用药时间出错切勿随意加倍。静脉注射需在监护下进行，确保输注速度适当，以降低肾损伤风险。\n    \u003C/p>\n    \u003Cp class=\"material-paragraph\">\n      特别提醒：唑来膦酸滴注当天须补充足够水分，但不建议大量饮水憋尿。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 04 常见不良反应及处理方案 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f3faff 80%, #fbe8e1 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">⚠️\u003C/span> 常见不良反应及处理方案\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\u003Cstrong>吡咯替尼：\u003C/strong>常见副作用包括腹泻、手脚麻木、轻度肝酶升高。极少发生心脏功能损害。部分患者口腔溃疡，出现严重反应需要及时报告医生。\u003C/li>\n      \u003Cli>\u003Cstrong>唑来膦酸：\u003C/strong>注射可能引起低血钙、肌肉疼痛，偶见发热。长期用药可能导致牙齿与下颌骨相关问题。提前牙科检查有助于风险规避。文献指出，唑来膦酸相关下颌骨坏死发生风险低于1%（Ruggiero et al., \"American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2022 Update\", J Oral Maxillofac Surg, 2022）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：发生胃肠道反应时要注意补水，轻微不适可短时观察，如症状加重或持续不退需就医。唑来膦酸用药期间定期监测肾功能、电解质。\n    \u003C/p>\n    \u003Cp class=\"material-case\">\n      一位患者使用唑来膦酸后短暂发热，但多喝水后症状消退，无需特殊处理。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 05 药品相互作用：服用须知 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f5faee 80%, #e5e5e7 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">🧡\u003C/span> 药品相互作用：服用须知\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>吡咯替尼：\u003C/strong>和强效CYP3A4抑制剂、诱导剂（如某些抗生素、抗癫痫药）同用可影响药效。服用此类药物时要主动告知医生。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>唑来膦酸：\u003C/strong>与氨基糖苷类抗生素齐用可能增加肾功能损伤风险。联合使用其他降钙药需密切监测。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：用药期间不得自行添加其他药品，换药或增减药品要经医生审核。间隔服用不是所有药品都有效，部分药物需严格避免同服。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 06 特殊人群与用药禁忌 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f2edf3 80%, #eaf6f3 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">👮️\u003C/span> 特殊人群与用药禁忌\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>老年人：\u003C/strong>肾功能下降时用药需调整剂量。选择吡咯替尼、唑来膦酸时建议先评估基础功能。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能不全者：\u003C/strong>吡咯替尼主要通过肝脏代谢，肝功能明显异常患者慎用或减量。唑来膦酸主要经肾排泄，肾功能不全禁用或遏制剂量（参考Jones et al., \"Zoledronic acid use in patients with renal impairment\", J Support Oncol, 2007）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇、哺乳期：\u003C/strong>目前缺乏足够数据证明安全性，孕期和哺乳期应避免使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过敏史：\u003C/strong>对吡咯替尼、唑来膦酸或相关成分过敏者禁止使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：首次用药前认真查看说明书禁忌条款，有特殊情况立即与医生沟通。\n    \u003C/p>\n    \u003Cp class=\"material-case\">\n      有位肾功能异常患者在静脉用药后出现肌酐升高，及时停药并调整方案后恢复。肾功能不全患者务必提前评估药物适应性。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 07 药品储存与保存要求 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #f6f7fa 80%, #f0fde7 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">📦\u003C/span> 药品储存与保存要求\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>吡咯替尼片：\u003C/strong>请放置在避光、干燥处，常温储存（一般为15-30℃）。原包装密封保存能减少受潮、受污染风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>唑来膦酸：\u003C/strong>应避光、密封，储存在原瓶或安瓿中，建议温度不高于30℃。开封后如有剩余，禁止存放再次使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：药品不要放在浴室、厨房等潮湿地带。儿童、宠物接触不到的地方最安全。过期药应交回药店处理，不可随意丢弃。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 08 遗漏服药及过量应对 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #edeefa 80%, #fce9fa 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">❓\u003C/span> 遗漏服药与过量应对\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cstrong>吡咯替尼漏服：\u003C/strong>发现后应尽快补服，若临近下次服药则跳过不补。切忌为补上漏服而加倍用药。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>唑来膦酸漏用：\u003C/strong>下次输注在规定时间内完成即可，无需提前加量。每次输注须按疗程严格执行，切勿自行调整频次。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量应对：\u003C/strong>一旦出现明显不适（如严重呕吐、抽搐、急性肾损伤症状等），应立即前往医院处理。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      正确做法：使用药物记录本可帮助提醒每日服药，减少漏服。家有老人或行动不便者，应以安全简明的提示方式管理药物。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 09 用药结语与操作总结 -->\n  \u003Cdiv class=\"material-subsection\" style=\"background: linear-gradient(90deg, #fdf6f6 80%, #e2f7fc 100%); margin-top:20px;\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">🌸\u003C/span> 用药小结：记住这些关键点\u003C/h2>\n    \u003Cp class=\"material-paragraph\">\n      总结一下，吡咯替尼和唑来膦酸要做到“四看”：看清成分与规格；看准给药方法和适应人群；关注药物可能的不良反应和相互作用；储存条件别弄错。务必遵循说明书和医嘱，出现任何疑问及时就医，安全用药永远排在第一位。\n    \u003C/p>\n    \u003Cul class=\"material-list\">\n      \u003Cli>按时服用，不自行加减药量\u003C/li>\n      \u003Cli>留意可能的副作用\u003C/li>\n      \u003Cli>药品妥善储存，避免误服和污染\u003C/li>\n      \u003Cli>就医和用药问题要主动沟通\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-paragraph\">\n      合理使用现代靶向药物与骨保护药，只要注意这些细节，疗效与安全都能更有保障。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 参考文献 -->\n  \u003Cdiv class=\"material-references\" style=\"background: linear-gradient(90deg, #f2f2f5 80%, #eaf7ef 100%); margin-top:20px; margin-bottom:32px;\">\n    \u003Ch3 class=\"material-ref-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\u003Cspan class=\"material-icon\">📚\u003C/span> Reference\u003C/h3>\n    \u003Col class=\"material-ref-list\">\n      \u003Cli>\n        Xu, B., Yan, M., Ma, F., et al. (2021). Pyrotinib as an irreversible pan-ErbB receptor tyrosine kinase inhibitor for HER2-positive breast cancer: A comprehensive review. \u003Cem>Cancer Communications\u003C/em>, 41(12), 1173-1189. https://doi.org/10.1002/cac2.12223\n      \u003C/li>\n      \u003Cli>\n        Jones, G. L., Saad, F., Body, J. J. (2007). Zoledronic acid use in patients with renal impairment. \u003Cem>Journal of Supportive Oncology\u003C/em>, 5(12), 563-568. PMID: 18259718\n      \u003C/li>\n      \u003Cli>\n        Ruggiero, S. L., Dodson, T. B., Fantasia, J., et al. (2022). American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2022 Update. \u003Cem>Journal of Oral and Maxillofacial Surgery\u003C/em>, 80(5), 920-943. https://doi.org/10.1016/j.joms.2022.02.008\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-bg {\n  background: #fcfcfc;\n  padding: 36px 0 18px 0;\n  margin: 0;\n  font-family: \"PingFang SC\", \"Microsoft YaHei\", Arial, sans-serif;\n  font-size: 19px;\n  line-height: 1.76;\n  color: #223645;\n}\n\n.material-title {\n  color: #335396;\n  font-size: 2.5em;\n  text-align: center;\n  padding: 12px 0;\n  margin-top: 0;\n  margin-bottom: 22px;\n  font-weight: 700;\n  letter-spacing: 3px;\n}\n\n.material-lead {\n  max-width: 820px;\n  margin: 0 auto 10px auto;\n  font-size: 1.13em;\n  background: rgba(248,249,251,0.7);\n  padding: 15px 26px;\n  border-left: 6px solid #b6bff5;\n  border-radius: 9px;\n}\n\n.material-section {\n  margin: 0 0 32px 0;\n}\n\n.material-subsection {\n  max-width: 880px;\n  margin-left: auto;\n  margin-right: auto;\n  border-radius: 13px;\n  box-shadow: 0 8px 22px 0 rgba(163,168,178,0.08);\n  padding: 30px 32px 18px 32px;\n}\n\n.material-subtitle {\n  font-size: 1.45em;\n  font-weight: 600;\n  padding-bottom: 12px;\n  margin-top: 0;\n  position: relative;\n  letter-spacing: 2px;\n}\n\n.material-icon {\n  font-size: 1.16em;\n  margin-right: 8px;\n  vertical-align: middle;\n}\n\n.material-list {\n  margin-top: 0.7em;\n  margin-bottom: 0.7em;\n  padding-left: 1.4em;\n  list-style-type: disc;\n}\n\n.material-list li {\n  margin-bottom: 0.53em;\n}\n\n.material-paragraph {\n  margin: 12px 0 10px 0;\n  font-size: 1.02em;\n  color: #314155;\n}\n\n.material-case {\n  margin: 8px 0 0 0;\n  font-size: 0.98em;\n  padding: 5px 16px;\n  border-left: 4px solid #e8bfae;\n  background: #f9f3ec;\n  color: #7a5941;\n  border-radius: 6px;\n}\n\n.material-references {\n  max-width: 870px;\n  margin: 0 auto;\n  padding: 20px 32px 14px 32px;\n  border-radius: 11px;\n}\n\n.material-ref-title {\n  font-size: 1.18em;\n  margin-bottom: 7px;\n  color: #225573;\n  font-weight: 600;\n  letter-spacing: 1px;\n}\n\n.material-ref-list {\n  font-size: 0.98em;\n  color: #354963;\n  list-style: decimal inside;\n  margin-left: 1.5em;\n  padding-left: 0;\n}\n\n.material-ref-list li {\n  margin: 0 0 5px 0;\n  padding: 0;\n}\n\n@media (max-width: 700px) {\n  .material-bg {\n    padding: 0.6em 0 1em 0;\n    font-size: 17px;\n  }\n  .material-title {\n    font-size: 1.6em;\n    padding: 7px 0;\n    margin-bottom: 12px;\n  }\n  .material-section,\n  .material-subsection,\n  .material-references {\n    padding: 15px 10px 10px 10px;\n    margin-bottom: 12px;\n  }\n  .material-subtitle {\n    font-size: 1.07em;\n    padding-bottom: 7px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"material-bg\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62,",505,"2025-07-28 11:53:59","乳腺癌, 吡咯替尼, 唑来膦酸, 靶向治疗, 药物不良反应, 安全用药","了解乳腺癌IV期患者的靶向治疗用药细节，包括吡咯替尼和唑来膦酸的用法、不良反应及注意事项，提高用药安全性，保障治疗效果。","2025-07-31 18:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]